OncoSec Medical Inc Stock Nasdaq
Equities
US68234L2079
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M 38.59M |
---|---|---|---|---|---|
Net income 2021 | -45M -61.26M | Net income 2022 | -34M -46.28M | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M 45.79M | Net cash position 2022 | 1.12M 1.53M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 20-10-11 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 21-02-17 |
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |